Vestor Capital’s ImmunityBio IBRX Stock Holding History

Vestor Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.1M	Buy	44,835 +33,299	+289%	+$252K	0.76%	38
2026 Q1	$88K	Buy	+11,536	New	+$79K	0.01%	205

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vestor Capital's IBRX Position: Q2 2026 in Review

Vestor Capital increased its ImmunityBio (IBRX) stake by 289% in Q2 2026, buying an estimated $252K and bringing the position to 44,835 shares worth $12.1M. The position accounts for 0.76% of the portfolio, ranked #38.

Vestor Capital first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Vestor Capital held 44,835 shares of ImmunityBio worth $12.1M as of Q2 2026.
Vestor Capital bought 33,299 ImmunityBio shares in Q2 2026, an estimated $252K.
ImmunityBio made up 0.76% of Vestor Capital's portfolio in Q2 2026, its #38 holding.
Vestor Capital first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Vestor Capital's 13F filing for Q2 2026, filed 28 Jul 2026.